U.S. markets closed
  • S&P 500

    3,744.52
    -38.76 (-1.02%)
     
  • Dow 30

    29,926.94
    -346.93 (-1.15%)
     
  • Nasdaq

    11,073.31
    -75.33 (-0.68%)
     
  • Russell 2000

    1,752.51
    -10.18 (-0.58%)
     
  • Crude Oil

    88.96
    +1.20 (+1.37%)
     
  • Gold

    1,720.90
    +0.10 (+0.01%)
     
  • Silver

    20.69
    +0.15 (+0.71%)
     
  • EUR/USD

    0.9795
    -0.0089 (-0.90%)
     
  • 10-Yr Bond

    3.8260
    +0.0670 (+1.78%)
     
  • GBP/USD

    1.1159
    -0.0163 (-1.44%)
     
  • USD/JPY

    145.1300
    +0.5200 (+0.36%)
     
  • BTC-USD

    20,014.13
    -28.15 (-0.14%)
     
  • CMC Crypto 200

    456.11
    -7.01 (-1.51%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    27,311.30
    +190.80 (+0.70%)
     

Why Hillstream BioPharma Shares Are Trading Higher Today?

·1 min read
  • Hillstream BioPharma Inc (NASDAQ: HILS) shares are trading higher after it authorized a share repurchase program to acquire up to $1 million in common stock.

  • As of March 31, Hillstream had approximately $11.1 million in cash and 11.4 million shares of common stock.

  • "We have demonstrated strong execution and, as a result, have seen significant advancement of our pipeline," said Randy Milby, Hillstream's CEO.

  • "The current market situation allows us to capture additional value for all investors through this measured buyback program. Our interests have always been and continue to be aligned with our shareholders," he added.

  • Hillstream BioPharma is working on a new anti-cancer mechanism resulting in iron-mediated cell death for drug-resistant and devastating cancers.

  • Hillstream's most advanced candidate is HSB-1216 targeting a variety of solid tumors.

  • Price Action: HILS shares are up 42.80% at $1.10 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.